The PDUFA date is May 29, 2026, two days from this release. Traders should position for binary outcome: approval would open a large new pediatric market (first needle-free insulin option in 100+ years) and likely drive significant upside. Rejection would be a major setback. The ADA data presentations provide supportive clinical context ahead of the decision.
MNKD drugs
MNKD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $3.55entry
- T+1 · 6mo ago +2.54%α +1.98% · $3.64
- T+5 · 6mo ago −3.38%α −4.59% · $3.43
- T+20 · 5mo ago +10.70%α +12.61% · $3.93
- T+60 · 3mo ago +20.00%α +18.12% · $4.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MannKind announced nine poster presentations at ADA 2026 covering Afrezza data in pediatric efficacy, treatment satisfaction, AID algorithm use, and gestational diabetes. The PDUFA target action date for Afrezza in pediatric patients (ages 4-17) is May 29, 2026, just two days after this press release. The data broadly support Afrezza's profile but the key catalyst is the upcoming FDA decision on pediatric approval.
Key Facts
- PDUFA target action date for Afrezza pediatric indication (ages 4-17) is May 29, 2026
- Nine poster presentations at ADA 2026 (June 5-8) including pediatric A1c, treatment satisfaction, AID algorithm, and gestational diabetes data
- If approved, Afrezza would be the first needle-free insulin option for pediatric patients in over 100 years
- FDA accepted sBLA for review in October 2025
- Afrezza is already approved for adults (age 18+) since June 2014 and in India and Brazil
Financial Impact
Pediatric approval would expand Afrezza's addressable patient population significantly; no specific revenue estimates provided
Risk Factors
- FDA may issue a Complete Response Letter (CRL) on safety/efficacy grounds, particularly given the boxed warning for bronchospasm and lung function decline in adults
- Pediatric population has additional safety considerations (lung development, hypoglycemia risk) that could delay or block approval
- Afrezza has a history of slow commercial adoption in adults; pediatric uptake may also be gradual
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302065 |
Track record
17 reports on MNKD
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +19.24% at T+60 after the Jun 2, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers